TRBJ2-4: A Potential Drug Target for Cell Growth and Differentiation

Target Name: TRBJ2-4

NCBI ID: G28625

TRBJ2-4

Other Name(s): TCRBJ2S4 | TRBJ24 | T cell receptor beta joining 2-4

TRBJ2-4: A Potential Drug Target for Cell Growth and Differentiation

TRBJ2-4 (TcRBJ2S4) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the TRBJ family of proteins, which are involved in the regulation of cell growth and differentiation.

One of the unique features of TRBJ2-4 is its structure. It consists of four domains: an N-terminal transmembrane domain, a coiled-coil domain, a src-like domain, and a C-terminal T-cell receptor (TCR) -like domain. The N-terminal and C-terminal domains give the protein its name, while the coiled-coil and src-like domains are unique to TRBJ2-4.

The N-terminal transmembrane domain is the protein's extracellular domain, and it is involved in the regulation of the cell's cytoplasmic environment. The coiled-coil domain is a structural element that gives the protein its unique 3D shape. It is involved in the regulation of the protein's stability and in its interactions with other proteins.

The src-like domain is a unique structure that is found only in TRBJ2-4. It is involved in the regulation of the protein's interactions with the cell's cytoskeleton and in the regulation of its stability.

TRBJ2-4 is a protein that has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its unique structure and its involvement in the regulation of cell growth and differentiation make it an attractive target for drug development.

One of the reasons why TRBJ2-4 is considered a potential drug target is its involvement in the regulation of cell cycle progression. TRBJ2-4 is a key regulator of the G1/S transition, which is the stage of cell growth where the cell prepares for cell division. Studies have shown that TRBJ2-4 plays a crucial role in regulating the G1/S transition and in preventing the cell from entering the S phase.

Another reason why TRBJ2-4 is considered a potential drug target is its involvement in the regulation of neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurogenic gradients. Studies have shown that TRBJ2-4 is involved in the regulation of neurodegenerative diseases and that its dysfunction may contribute to the development and progression of these diseases.

In addition to its involvement in cell cycle progression and neurodegenerative diseases, TRBJ2-4 is also considered a potential drug target for cancer. Cancer is a disease that is characterized by the rapid and uncontrolled growth of cells. Studies have shown that TRBJ2-4 is involved in the regulation of cell growth and that its dysfunction may contribute to the development and progression of cancer.

Overall, TRBJ2-4 is a protein that is involved in the regulation of cell growth and differentiation. Its unique structure and its involvement in the regulation of cell cycle progression, neurodegenerative diseases, cancer, make it an attractive target for drug development. Further studies are needed to fully understand the function of TRBJ2-4 and its potential as a drug target.

Protein Name: T Cell Receptor Beta Joining 2-4

Functions: J region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBJ2-4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBJ2-4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets